Arcus Biosciences, Inc.
RCUS· NYSE
Released Nov 6, 2024, after the close
10-Q filed Nov 6, 2024, 37 days after period end · 0001724521-24-000160
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $7.00M | $32.00M | $33.00M | $9.46M |
| Net Income | -$92.00M | -$71.00M | -$65.00M | -$77.98M |
| EPS Diluted |
Arcus Biosciences, Inc. · CIK 1724521 · Engraved from SEC EDGAR
| -$1.00 |
| -$0.94 |
| -$0.90 |
| -$1.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.